RT Journal Article
SR Electronic
T1 Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000891
DO 10.1136/jitc-2020-000891
VO 8
IS 2
A1 Motzer, Robert J
A1 Escudier, Bernard
A1 McDermott, David F
A1 Arén Frontera, Osvaldo
A1 Melichar, Bohuslav
A1 Powles, Thomas
A1 Donskov, Frede
A1 Plimack, Elizabeth R
A1 Barthélémy, Philippe
A1 Hammers, Hans J
A1 George, Saby
A1 Grünwald, Viktor
A1 Porta, Camillo
A1 Neiman, Victoria
A1 Ravaud, Alain
A1 Choueiri, Toni K
A1 Rini, Brian I
A1 Salman, Pamela
A1 Kollmannsberger, Christian K
A1 Tykodi, Scott S
A1 Grimm, Marc-Oliver
A1 Gurney, Howard
A1 Leibowitz-Amit, Raya
A1 Geertsen, Poul F
A1 Amin, Asim
A1 Tomita, Yoshihiko
A1 McHenry, M Brent
A1 Saggi, Shruti Shally
A1 Tannir, Nizar M
YR 2020
UL http://jitc.bmj.com/content/8/2/e000891.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.